Dysregulation of HSG triggers vascular proliferative disorders

Nature Cell Biology

Volumn 6, Issue 9, 2004, Pages 872-883

  Chen, Kuang Hueih ^a,b   Guo, Xiaomei ^b   Ma, Dalong ^c   Guo, Yanhong ^a   Li, Qian ^a   Yang, Dongmei ^b   Li, Pengfei ^a   Qiu, Xiaoyan ^c   Wen, Shaojun ^a   Xiao, Rui Ping ^a,b   Tang, Jian ^a  

^a PEKING UNIVERSITY   (China)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COMPLEMENTARY DNA; MITOFUSIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CLONING; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TRANSFER; KNOCKOUT MOUSE; MALE; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RAT STRAIN; RESTENOSIS; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CELL DIVISION; CORONARY RESTENOSIS; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; ONCOGENE PROTEIN P21(RAS); RATS;

ANIMALIA;

EID: 4444270915     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1161     Document Type: Article

References (49)

1. Novak, K. Cardiovascular disease increasing in developing countries. Nature Med. 4, 989-990 (1998).
2. Tunstall-Pedoe, H. et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353, 1547-1557 (1999).
3. Dzau, V. J., Braun-Dullaeus, R. C. & Sedding, D. G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nature Med. 8, 1249-1256 (2002).
4. Forrester, J. S., Fishbein, M., Helfant, R. & Fagin, J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J. Am. Coll. Cardiol. 17, 758-769 (1991).
5. Braun-Dullaeus, R. C., Mann, M. J. & Dzau, V. J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98, 82-89 (1998).
6. Libby, P. Vascular biology of atherosclerosis: overview and state of the art. Am. J. Cardiol. 91, 3A-6A (2003).
7. Nabel, E. G. et al. Recombinant plate let-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J. Clin. Invest. 91, 1822-1829 (1993).
8. Nabel, E. G. et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362, 844-846 (1993).
9. Taylor, D. S. et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc. Natl Acad. Sci. 96, 1633-1638 (1999).
10. Dobrowolski, S., Harter, M. & Stacey, D. W. Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells. Mol. Cell Biol. 14, 5441-5449 (1994).
11. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
12. Peeper, D. S. et al. Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177-181 (1997).
13. kip1 degradation independently of cdk2/cyclin E in NIH 3T3 cells. J. Biol. Chem. 276, 34958-34965 (2001 ).
14. Leone, G., DeGregori, J., Sears, R., Jakoi, L. & Nevins, J. R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387, 422-426 (1997).
15. KIP1. Mol. Cell. Biol. 17, 3850-3857 (1997).
16. Ferguson, J. E. & Patterson, C. Break the cycle: the role of cell-cycle modulation in the prevention of vasculoproliferative diseases. Cell Cycle 2, 211-219 (2003).
17. Santel, A. & Fuller, M. T. Control of mitochondrial morphology by a human mitofusin. J. Cell Sci. 114, 867-874 (2001).
18. Rojo, M., Legros, F., Chateau, D. & Lombès, A. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J. Cell Sci. 115, 1663-1674 (2002).
19. Karbowski, M. et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J. Cell Biol. 159, 931-938 (2002).
20. Chen, H. et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol. 160, 189-200 (2003).
21. Hales, K. G. & Fuller, M. T. Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase. Cell 90, 121-129 (1997).
22. Okamoto, K. & Aoki, K. Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J. 27, 282-293 (1963).
23. Johns, D. G., Webb, R. C. & Charpie, J. R. Impaired ceramide signaling in spontaneously hypertensive rat vascular smooth muscle: a possible mechanism for augmented cell proliferation. J. Hypertens. 19, 63-70 (2001).
24. Bing, O. H. et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J. Mol. Cell. Cardiol. 27, 383-396 (1995).
25. Clowes, A., Reidy, M. & Clowes, M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49, 327-333 (1983).
26. Clowes, A. W. & Schwartz, S. M. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res. 56, 139-145 (1985).
27. Hanke, H., Strohschneider, T., Oberhoff, M., Betz, E., & Karsch, K. R. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ. Res. 67, 651-659 (1990).
28. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W. & Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749 (1990).
29. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
30. Kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880 (1996).
31. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
32. Kip1-deficient mice. Cell 85, 733-744 (1996).
33. Harbour, J. W. & Dean, D. C. Rb function in cell-cycle regulation and apoptosis. Nature Cell Biol. 2, E65-E67 (2000).
34. DeGregori, J., Kowalik, T. & Nevins, J. R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15, 4215-4224 (1995).
35. Garars, S. M., Huber, P. & Scott, N. A. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol. Ther. 92, 165-178 (2001).
36. Moses, J. W. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315-1323 (2003).
37. Woods, T. C. & Marks, A. R. Drug eluting stents. Anno. Rev. Med. 55, 169-178 (2004).
38. Morishita, R. Recent progress in gene therapy for cardiovascular disease. Circ. J. 66, 1077-1086 (2002).
39. Chang, M. W. et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267, 518-522 (1995).
40. Chang, M. W., Barr, E., Lu, M. M., Barton, K. & Leiden, J. M. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96, 2260-2268 (1995).
41. Ohno, T. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781-784 (1994).
42. Ooboshi, H., Rios, C. D. & Heistad, D. D. Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo. Mol. Cell. Biochem. 172, 37-46 (1997).
43. Tulis, D. A. et al. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 104, 2710-2715 (2001).
44. Maillard, L. et al. Effect of percutaneous adenovirus-mediated Gaxgene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Ther. 7, 1353-1361 (2000).
45. Kim, S. et al. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J. Clin. Invest. 100, 1006-1014 (1997).
46. Chakir, K. et al. The third intracellular loop and the carboxyl terminus of J12-adrenergic receptor confer the receptor spontaneous activity. Mol. Pharmacol. 64, 1048-1058 (2003).
47. Devlin, A.M The effects of perindopril on vascular smooth muscle polyploidy in strokeprone spontaneously hypertensive rats. J. Hypertens. 13, 211-218 (1995).
48. Feliciello, I & Chinali, G. A modified alkaline lysis method for the preparation of highly purified plasmid DNA from Escherichia coli. Anal. Biochem. 212, 394-401 (1993).
49. Benson, D. A. et al. GenBank. Nucleic Acids Res. 27, 12-17 (1999).